ESMO ESMO 2022: Highlights on neo-adjadjuvant vs adjuvant pembrolizumab in resected stage III-IV melanoma: SWOG S1801 By ONA Editor September 22, 2022 No Comments Share Tweet Pinterest LinkedIn Tumblr Email + Share. Twitter Facebook Pinterest LinkedIn Tumblr Email